At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

It holds more than 40% of the US market share. Gilead Sciences Inc. (NASDAQ:GILD) is now developing lenacapavir for twice-yearly HIV prevention with regulatory filings underway in the US and Europe.